Oncomatryx Biopharma S. L. is a pharmaceutical biotechnology company that develops personalized treatments against invasive cancer as well as tests for its early detection. Established by Laureano Simón, PhD, Oncomatryx thus engages twofold in the fight against invasive kinds of cancer, such as pancreatic cancer or invasive breast cancer, all of which have high mortality rates. Oncomatryx's research focuses on peritumoral stroma, which has been found to take part in promoting cancer invasiveness and curtailing treatment efficacy. Laureano Simón Laureano Simón began his business career in 2000 with the creation of Progenika Biopharma S.A., a personalized medicine company which was acquired by Grifols in February 2013. Dr. Simón holds a Ph.D. in Chemical Sciences (Molecular Biology) by the Universidad Autónoma de Madrid, a master's degree in Biotechnology by the University of Navarra, an MSc by the “University of Wisconsin-Madison” and a bachelor's degree in Pharmacy by the University of Santiago de Compostela. He has patented, among others, clinical products such as BLOODchip and LIPOchip. Research and development The company bases its R&D on the recent discovery that tumor cells generate changes in the cells that surround them as well as in the extracellular matrix, facilitating invasion metastases. Oncomatryx and its collaborators and advisors have proved that peritumoral stroma, which is constituted by mesenchymal cells and extracellular matrix, plays a key role in tumor invasiveness and metastasis, at the same time being a physical barrier that prevents anti-cancer agents from reaching tumor cells. Oncomatryx is developing a new generation of biological anti-tumor drugs, combining cytotoxic molecules and monoclonal antibodies specifically directed towards tumor associated stroma. Scientific Advisory Board Franco Dosio, Ph.D. Professor, Department of Drug Science and Technology. Università degli Studi di Torino. Torino, Italy. Tomás Girbés, Ph.D. Professor. Departament of Nutrition and Bromatology. Facultad de Medicina. Universidad de Valladolid, CINAD. Valladolid, Spain. Manuel Hidalgo, M.D., Ph.D. Head of Gastrointestinal Cancer Clinical Research unit. Centro Nacional de Investigaciones Oncológicas. Madrid, Spain. Roland E. Kontermann, Ph.D. Mildred-Scheel Professor. Biomedical Engineering unit. Institut für Zellbiologie und Immunologie. Universität Stuttgart. Germany. Klaus Pfizenmaier, Ph.D. Professor, Director of Institute. Cell Biology unit. Institut für Zellbiologie und Immunologie. Universität Stuttgart. Germany. Andrea Bolognesi, Phd. Professor. Department of Experimental Diagnosticand Speciality Medicine. Universitá Bologna, Italy. Collaborations Oncomatryx collaborates with the Institut für Zell Biologie und Immunologie of the University of Stuttgart, the University of Valladolid, Hospital Universitario Marqués de Valdecilla, Hospital Universitario Central de Asturias, the Centro